Cika wannan jumla: Assertio Therapeutics ya mallaki Nucynta ER da Nucynta IR a baya. A ranar 15 ga Janairu, 2015, Depomed ya ba da sanarwar sayen ikon mallakar Tapentadol ((Nucynta) daga Janssen Pharmaceutica don tsabar kudi. Kasuwancin ya rufe a ranar 2 ga Afrilu, 2015, kuma an sake dawo da kayayyakin a watan Yunin 2015 bayan babban fadada karfin tallace-tallace. Bayan
Guguwar Maria a shekara ta 2017 kamfanin ya fuskanci babban karancin maganin saboda wurin masana'antar da ke Puerto Rico. A cikin Janairu 2018, bayan ƙasa da shekaru 3, an sayar da haƙƙin masana'antar Nucynta don dala miliyan 10 kawai tare da dala miliyan 135 a cikin haƙƙin mallaka na shekaru 4 na farko. A yanzu ana samar da Tapentadol don kasuwar Amurka da Kanada ta Collegium Pharmaceutical.